- Home
- BIIB vs PHM Comparison
BIIB vs PHM Comparison
Compare BIIB & PHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PHM
- Stock Information
- Founded
- BIIB 1978
- PHM 1950
- Country
- BIIB United States
- PHM United States
- Employees
- BIIB N/A
- PHM 6793
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PHM Homebuilding
- Sector
- BIIB Health Care
- PHM Consumer Discretionary
- Exchange
- BIIB Nasdaq
- PHM Nasdaq
- Market Cap
- BIIB 18.7B
- PHM 27.0B
- IPO Year
- BIIB 1991
- PHM N/A
- Fundamental
- Price
- BIIB $143.85
- PHM $134.64
- Analyst Decision
- BIIB Buy
- PHM Buy
- Analyst Count
- BIIB 27
- PHM 14
- Target Price
- BIIB $188.09
- PHM $136.71
- AVG Volume (30 Days)
- BIIB 1.5M
- PHM 2.0M
- Earning Date
- BIIB 10-29-2025
- PHM 10-21-2025
- Dividend Yield
- BIIB N/A
- PHM 0.64%
- EPS Growth
- BIIB 31.67
- PHM 2.26
- EPS
- BIIB 10.45
- PHM 13.40
- Revenue
- BIIB $9,997,000,000.00
- PHM $17,694,541,000.00
- Revenue This Year
- BIIB $2.00
- PHM N/A
- Revenue Next Year
- BIIB N/A
- PHM $0.08
- P/E Ratio
- BIIB $13.86
- PHM $10.23
- Revenue Growth
- BIIB 3.36
- PHM 5.04
- 52 Week Low
- BIIB $110.04
- PHM $88.07
- 52 Week High
- BIIB $204.18
- PHM $149.47
- Technical
- Relative Strength Index (RSI)
- BIIB 57.77
- PHM 56.78
- Support Level
- BIIB $139.54
- PHM $134.21
- Resistance Level
- BIIB $150.28
- PHM $139.69
- Average True Range (ATR)
- BIIB 4.43
- PHM 3.22
- MACD
- BIIB 0.46
- PHM -0.46
- Stochastic Oscillator
- BIIB 62.26
- PHM 41.55
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.